Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback